Lind Value II ApS Sells 55,847 Shares of InMode Ltd. $INMD

Lind Value II ApS trimmed its holdings in InMode Ltd. (NASDAQ:INMD) by 31.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,093 shares of the healthcare company’s stock after selling 55,847 shares during the quarter. InMode makes up about 0.6% of Lind Value II ApS’s holdings, making the stock its 7th biggest position. Lind Value II ApS’s holdings in InMode were worth $1,779,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. ARGA Investment Management LP increased its holdings in shares of InMode by 355.0% in the 3rd quarter. ARGA Investment Management LP now owns 143,658 shares of the healthcare company’s stock valued at $2,141,000 after acquiring an additional 112,087 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in shares of InMode in the 3rd quarter valued at $1,564,000. State of New Jersey Common Pension Fund D increased its holdings in shares of InMode by 612.1% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 96,120 shares of the healthcare company’s stock valued at $1,432,000 after acquiring an additional 82,621 shares during the period. Doma Perpetual Capital Management LLC increased its holdings in shares of InMode by 26.8% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock valued at $42,293,000 after acquiring an additional 599,108 shares during the period. Finally, Ancient Art L.P. acquired a new position in shares of InMode in the 3rd quarter valued at $14,254,000. 68.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Barclays set a $19.00 price objective on shares of InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. Robert W. Baird reduced their price objective on shares of InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Finally, BTIG Research reiterated a “neutral” rating on shares of InMode in a research report on Monday, January 26th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $16.00.

InMode Stock Performance

Shares of NASDAQ INMD opened at $13.74 on Friday. InMode Ltd. has a one year low of $12.72 and a one year high of $16.74. The firm has a market capitalization of $870.57 million, a P/E ratio of 10.10 and a beta of 1.97. The company’s fifty day moving average is $13.90 and its two-hundred day moving average is $14.24.

InMode (NASDAQ:INMD) last released its quarterly earnings data on Wednesday, May 6th. The healthcare company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). The company had revenue of $82.02 million for the quarter, compared to analysts’ expectations of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.31 EPS.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.